Conventional chemotherapy is the mainstay of adjuvant systemic treatment for most patients with early triple-negative breast cancer (TNBC). At present, comparisons between adjuvant chemotherapy regimens are retrospective in nature, and so the optimal drugs or drug combinations have not been established for patients with early TNBC. In retrospective subgroup analyses, taxanes are more effective than 5-fluorouracil in combination with cyclophosphamide and doxorubicin. Classical CMF (cyclophosphamide, methotrexate and 5-fluorouracil) has shown efficacy, whereas few data on the role of anthracyclines are available. An unplanned subgroup analysis of one randomised study suggests that capecitabine adds efficacy to a taxane-anthracycline regimen, but this observation requires confirmation. High-dose adjuvant chemotherapy is considered experimental. Ongoing trials are comparing standard adjuvant regimens with regimens that integrate an anti-angiogenic agent, a platin or maintenance capecitabine. Inhibitors of DNA repair or specific tyrosine kinases have not yet been addressed in the adjuvant setting. In the absence of data from prospective trials that focus on adjuvant therapy of early TNBC, several regimens, such as a taxane and an anthracycline-containing regimen or classical CMF may be considered reasonable choices.
introduction Adjuvant therapy for breast cancer prolongs disease-free survival (DFS) and overall survival, but does not benefit all breast cancer patients. For example, targeted agents, such as adjuvant tamoxifen and trastuzumab are not universally beneficial. These approaches do not benefit women with triplenegative breast cancer (TNBC), which is characterised by the lack of expression of oestrogen receptors (ER) and progesterone receptors (PgR), and lack of human epidermal growth factor receptor 2 (HER2) overexpression. TNBCs are generally aggressive tumours that occur frequently in younger women (<50 years) and tend to metastasise to visceral sites rather than to bone. TNBC is a heterogeneous disease comprising approximately 15% of all breast cancers and shares similarities with basal-like breast cancer, claudin-low breast cancer and BRCA1-related disease [1] [2] [3] . Here, we review the current literature on adjuvant chemotherapy for TNBC.
PubMed and clinicaltrials.gov databases were searched using the terms 'triple-negative breast cancer' and 'adjuvant chemotherapy' for publications in the last 5 years (2006-2011) (N = 140 references, but not one prospective adjuvant trial). Additional references were identified through spot searches on select topics, including abstracts for the American Society of Clinical Oncology (2009-2011), San Antonio Breast Cancer Congress (2009) (2010) and the ECCO-ESMO Multidisciplinary Cancer Congress (2009) (2010) .
outcomes from clinical trials on adjuvant chemotherapy in TNBC
In the absence of a specific therapeutic target, conventional chemotherapy is the mainstay of TNBC treatment according to the majority of national and international guidelines (e.g. NCCN [4] , St Gallen [5] , St Paul de Vence [6] , AGO and ESMO [7] ). This is important because retrospective data [8] suggest a strong association between guideline adherence and relapse-free survival/overall survival of patients with TNBC. Currently available data on the impact of adjuvant chemotherapy in TNBC are limited and retrospective in nature, and much of our knowledge on chemosensitivity of TNBC comes from retrospective subgroup analyses of neoadjuvant trials [1, 9] .
classical CMF and anthracycline regimens
Classical CMF (cyclophosphamide, methotrexate and 5fluorouracil) is reportedly effective in the treatment of TNBC. The International Breast Cancer Study Group (IBCSG) trials VIII and IX compared three or six courses of CMF (with or without endocrine therapy) with endocrine therapy alone. An analysis of these trials, based on centrally assessed ER, PgR and HER2 status, showed a benefit for CMF over endocrine therapy only in the subset of women with TNBC [N = 303; hazard ratio (HR) 0.46; 95% confidence interval (CI) 0.29-0.73; interaction P = 0.009 versus endocrine receptor-present disease] [10] .
Anthracycline-containing regimens are effective in the treatment of TNBC in the neoadjuvant setting [11] , but the role of anthracyclines is not well established in the adjuvant treatment of TNBC. For example, the MA5 adjuvant trial compared classical CMF with Canadian CEF (cyclophosphamide, epirubicin and 5-fluorouracil) in premenopausal women with node-positive early breast cancer. Somewhat unexpectedly, a retrospective analysis, based on small numbers and published thus far only in an abstract form, found classical CMF to be associated with significantly better 5-year survival than CEF (71% versus 51%, respectively) in the subset of women who had breast cancer of the basal phenotype (defined as negative for hormone receptors and HER2, positive for cytokeratin 5/6 or epidermal growth factor receptor) [12] . In contrast, a post-hoc analysis of a phase III trial reported that, in patients with triple-negative rapidly proliferating breast cancer, adjuvant CMF was inferior to the combination of epirubicin plus CMF in terms of 5-year DFS (59% versus 85%, respectively; P = 0.002) and overall survival (73% versus 91%, respectively; P = 0.002) [13] .
taxane regimens
Subset analyses of several large trials suggest that taxane combinations (with cyclophosphamide and doxorubicin) are beneficial in the treatment of TNBC and may be more effective in this subset than chemotherapy combinations that do not include a taxane [14] . A meta-analysis of 12 randomised clinical trials shows that adjuvant docetaxel-based chemotherapy compared with regimens without taxanes is associated with an improvement in DFS and overall survival in TNBC [14] . The GEICAM 9805 study showed that docetaxel, doxorubicin and cyclophosphamide (TAC) is more effective than fluorouracil, doxorubicin and cyclophosphamide (FAC) in the adjuvant treatment of high-risk node-negative breast cancer [15] . Planned subgroup analyses of DFS in subsets of patients by hormone receptor and HER2 status are depicted in Figure 1 [15] . Patients with HER2-negative tumours showed the highest DFS benefit. In the TNBC subset ( Figure 1D ), the HR for DFS was 0.59 (95% CI 0.32-1.07; P = 0.08) favouring TAC over FAC [15] . The Breast Cancer International Research Group (BCIRG) 001 study also demonstrated TAC to be more effective than FAC in the adjuvant treatment of node-positive TNBC [16] . Subgroup analyses addressing 3-year DFS showed a non-significant trend (P = 0.051) in the TNBC subgroup in favour of TAC over FAC (74% versus 60%, respectively; HR 0.50; 95% CI 0.29-1.00).
Hayes et al. [17] investigated whether paclitaxel added after adjuvant AC was equally beneficial to all biological subgroups enrolled in the CALGB9344 study by immunohistochemical testing of tissue blocks from 1322 women for HER2 positivity. Paclitaxel was associated with improved DFS in the subset of women with HER2-negative, ER-negative tumours (Figure 2A ). Paclitaxel also benefited the subgroup with HER2-positive cancer independent of the ER status ( Figure 2C and D), but not the HER2-negative, ER-positive group ( Figure 2B ). Exploratory analyses have shown differential effects of taxanes in women with TNBC according to schedule. Similar to findings in the general breast cancer population, weekly paclitaxel was associated with improved DFS (HR 1.37; 95% CI 0.98-1.93) and overall survival (HR 1.33; 0.91-1.94) in patients with TNBC compared with standard therapy ( paclitaxel every 3 weeks) [18] .
capecitabine regimens
Patients often prefer the convenience of an oral treatment versus intravenous chemotherapy. Capecitabine has been investigated in the adjuvant setting for the prevention of breast cancer recurrence. Single-agent capecitabine was inferior to standard adjuvant chemotherapy (classical CMF or AC) in the CALGB49907 trial, which included women aged 65 years or older with early-stage breast cancer [19] . Unplanned subgroup analyses showed that patients with hormone receptor-negative cancer benefited more from standard therapy than from capecitabine. In the FINXX adjuvant study, three cycles of docetaxel plus capecitabine (TX) followed by three cycles of CEX (cyclophosphamide, epirubicin and capecitabine) showed a trend for improved 5-year recurrence-free survival (RFS) compared with three cycles of docetaxel (T) followed by three cycles of CEF (T-CEF; 87% versus 84%, respectively; HR 0.79; 95% CI 0.60-1.04; P = 0.087) [20, 21] . In an exploratory analysis of the TNBC subgroup consisting of 202 patients, TX-CEX was associated with longer RFS compared with T-CEF (HR 0.48; 95% CI 0.26-0.88; P = 0.018). In the US Oncology phase III adjuvant study, 2611 patients received four cycles of AC followed by four cycles of docetaxel with or without capecitabine (AC-TX or AC-T, respectively) [22] . After 5-years' follow-up, DFS (the primary objective) in the capecitabine arm (AC-TX) was 89% versus 87% in the AC-T arm (P = 0.125). Overall survival (a secondary objective) was significantly better in the AC-TX arm (P = 0.011). Therefore, more data are needed on the benefits and harms of capecitabine when it is integrated into current adjuvant regimens, and the current role of capecitabine thus remains unestablished in the treatment of early TNBC.
future strategies for adjuvant treatment of TNBC
There are several ongoing studies (including BEATRICE, CIBOMA/2004-01, FNCLCC-PACS-08, TITAN) for the Figure 2 . Disease-free survival among patients treated with or without paclitaxel according to oestrogen-receptor status and HER2 expression in the CALGB 9344 study. Reproduced with permission from the Massachusetts Medical Society [17] . ©2010 Massachusetts Medical Society. Patients were randomly assigned to receive four cycles of paclitaxel (175 mg/m 2 ) or no further chemotherapy with paclitaxel after completion of four cycles of doxorubicin and cyclophosphamide. adjuvant treatment of TNBC (Table 1 ). These include phase III trials that explore the addition of capecitabine, bevacizumab, ixabepilone and platinum agents to standard adjuvant chemotherapy. A phase I/II study is looking at concurrent treatment with carboplatin and radiation therapy.
The CIBOMA/2004-01 is a phase III trial of adjuvant capecitabine (maintenance therapy after standard chemotherapy) in TNBC. Preliminary safety analyses on 405 patients report seven serious adverse events related to capecitabine treatment, including hospitalisation for grade 2-4 diarrhoea, grade 2 thoracic pain, grade 2 arrhythmia, coronary vasospasm and chest pain [23] .
Other studies, either in TNBC or in metastatic breast cancer, are investigating novel compounds. In the event of positive results, these compounds could proceed to testing in the adjuvant setting.
platinums
Following promising results in the neoadjuvant setting, there has been renewed interest in platinums either as a single agent or in combination therapy for TNBC after prior exposure to classical agents such as anthracyclines, cyclophosphamide and taxanes [24] . Their use is supported by the high frequency of germline mutations in the BRCA1 gene in TNBC tumours. Tumours with BRCA1 mutation have a reduced capacity for DNA repair, and thus are unable to completely recover from the effects of DNA-damaging agents, promoting tumour cell apoptosis. In addition, the p53 family member p63 has been shown to control a survival pathway that directly mediates cisplatin sensitivity in TNBC. In vitro, co-expression of p63/ p73 in TNBC tumours was shown to predict for cisplatin sensitivity in TNBC, but not for other standard chemotherapy agents, warranting further investigation of p63/p73 as biomarkers to predict response to platinum therapy in TNBC [25] . The use of platinums for the adjuvant treatment of TNBC is still under investigation, and is not currently recommended in this setting.
anti-angiogenic agents
Bevacizumab [anti-vascular endothelial growth factor (VEGF) monoclonal antibody] has been evaluated in large phase III clinical trials in combination with paclitaxel [26] , docetaxel [27] or capecitabine [28] as first-line [26] [27] [28] and second-line [29] treatment of metastatic breast cancer. Subgroup analyses of these studies suggested similar progression-free survival (PFS) benefits for bevacizumab plus a taxane in patients with TNBC and those with non-TNBC [26, 27] . Adjuvant bevacizumab in combination with taxanes is being prospectively investigated in TNBC in the BEATRICE trial.
epidermal growth factor receptor-targeted agents
Epidermal growth factor receptor (EGFR)-targeted agents are being studied in TNBC given the high-level EGFR of expression in some of these cancers, for example the phase II BALI study reported that the combination of the anti-EGFR monoclonal antibody cetuximab and cisplatin improved PFS versus cisplatin alone in TNBC (3.7 versus 1.5 months; P = 0.03) [30] . An evaluation of the combination of a standard chemotherapy (FEC100 followed by docetaxel) with panitumumab as neoadjuvant therapy of operable TNBC was recently reported with a pathological complete response rate of 65% [31] .
EGFR inhibitors have demonstrated low efficacy as single agents in TNBC, but in combination may improve the efficacy of other agents, such as taxanes or platinums. 
high-dose chemotherapy (HDC)
Several retrospective subset analyses suggest that high-dose chemotherapy (HDC) is effective in TNBC patients. In the WSG AM-01 adjuvant trial in high-risk breast cancer, patients were randomly assigned to dose-dense conventional chemotherapy [four cycles of epirubicin plus cyclophosphamide (EC) followed by three cycles of intravenous CMF, each administered every 2 weeks] or two cycles of dosedense EC followed by two cycles of HDC [33] . The high-dose arm showed significant improvement in 5-year event-free survival (62% versus 41%; HR 0.60; 95% CI 0.43-0.85; P = 0.004) and overall survival (76% versus 61%; HR 0.58; 95% CI 0.39-0.87; P = 0.007) compared with the dose-dense arm [33] .
In a multivariate analysis, young patients (≤50 years) with TNBC benefited most from the HDC regimen [33] . On the other hand, in a retrospective analysis carried out by Rodenhuis et al. [34] , there was little difference in the benefit obtained with HDC between patients who had ER-positive or ER-negative breast cancer. Two meta-analyses of 15 randomised high-risk primary breast cancer trials were recently published. The first one included 6102 patients and showed 13% event-free survival benefit in favour of HDC (P = 0.0001) over standard-dose chemotherapy at a median 6-year follow-up, but there was no significant difference in breast cancer-specific survival or overall survival [35] . HDC is also frequently associated with severe adverse effects. The second analysis included 6210 patients and showed a 13% RFS benefit for HDC (P < 0.001) [36] . Overall survival was not statistically different by treatment arm in any of the subgroups except for women with HER2negative disease, for whom there was a 21% reduction in the risk of death; this reduction was greatest (33%) among patients with TNBC.
In summary, HDC remains an experimental approach in the adjuvant treatment of TNBC. Results from adjuvant dosedense treatment in hormone receptor-negative breast cancer are promising, but further data are required before dose-dense chemotherapy can be considered the standard of care [37] . conclusions Data on the impact of adjuvant chemotherapy in TNBC are limited and retrospective in nature. Current evidence shows that patients with TNBC benefit from adjuvant chemotherapy regimens containing standard agents. There is no universally accepted standard chemotherapy regimen for adjuvant treatment of TNBC, and several regimens, such as classical CMF, and anthracycline and taxane-containing regimens are currently reasonable choices. HDC remains an experimental approach. Studies that address novel agents, platinum compounds and different methods of drug administration are ongoing for the adjuvant treatment of TNBC or for metastatic breast cancer, and the results are eagerly awaited.
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